Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran

NCT05097664 | Unknown

• 1 other identifier: IR.MUI.MED.REC.1400.572
• Study Type: observational
• Target: 250
• Locations: 1 country
• Sites: 1

Brief Summary

Coronavirus disease 2019 (COVID-19) infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may manifest as a variety of disease patterns, ranging from mild to life-threatening pneumonia. Mucormycosis has been suspected to cause significant morbidity in infected people since the outbreak of the COVID-19 pandemic. Individuals who require hospitalization and intensive care are more vulnerable, as they have reached an advanced stage of their disease. Investigators will discuss the major risk factors, ocular presentation, and outcome of mucormycosis in individuals infected with SARS-CoV-2 in this study. From August 2021 to January 2022, a cross-sectional descriptive multicenter investigation would be conducted on patients with biopsy-confirmed mucormycosis and RTPCR confirmed COVID19. Demographic data, the time interval between COVID19 and mucormycosis, underlying systemic disorders, clinical characteristics, disease course, and outcomes would be analyzed.

Conditions

COVID-19; Mucormycosis

Keywords

Coronavirus Disease-Associated Mucormycosis; COVID-19; Rhino-orbital-cerebral mucormycosis; Mucormycosis

Outcome Measures

Primary Outcomes (1)

• Vision loss

  Prevalence of Vision loss in COVID-19 patients with Mucormycosis co-infection

  3 months

Secondary Outcomes (1)

• Risk factors

  3 months

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with Coronavirus Disease-Associated Mucormycosis

You may qualify if:

• Diagnosed case of Mucormycosis in COVID-19 pandemic

You may not qualify if:

• People with acute or severely ill conditions that prevent them from ophthalmic examination.
• Patient, or legal representative opposing the pursuit of the research

Sponsors & Collaborators

• Isfahan University of Medical Sciences: lead
• Shiraz University of Medical Sciences: collaborator
• Ahvaz Jundishapur University of Medical Sciences: collaborator
• Iran University of Medical Sciences: collaborator
• Mashhad University of Medical Sciences: collaborator
• Tabriz University of Medical Sciences: collaborator
• Guilan University of Medical Sciences: collaborator
• Kermanshah University of Medical Sciences: collaborator
• Shahid Beheshti University of Medical Sciences: collaborator
• Semnan University of Medical Sciences: collaborator

Study Sites (1)

Isfahan University of Medical Sciences

Isfahan, +98, Iran

RECRUITING

Related Publications (1)

• Eshraghi B, Khademi B, Bahmani Kashkouli M, Khataminia G, Kiarudi MY, Nabie R, Abounoori M, Chaibakhsh S, Ghahvehchian H, Rastegarnasab F, Parandin M, Zia Z, Karamirad S, Jafarpour S, Fakoor M, Varshochi M, Mirmohammadkhani M, Ramezani-Majd A, Janipour M, Mahdian Rad A, Shekarchian F, Manouchehri V, Sajjadi SMJ, Etezad Razavi M, Khosropour H, Forouhari A, Ebrahimi F, Pourazizi M. One-Year Patient Survival After COVID-19-Associated Rhino-Orbital-Cerebral Mucormycosis: A Multicenter Study. Mycopathologia. 2025 Jul 6;190(4):63. doi: 10.1007/s11046-025-00966-2.

  PMID: 40619554 DERIVED

MeSH Terms

Conditions

COVID-19; Mucormycosis

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Zygomycosis; Mycoses; Bacterial Infections and Mycoses

Study Officials

• Mohsen Pourazizi, M.D.

  Isfahan Eye Research Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Mohsen Pourazizi, M.D.

CONTACT

00983134452036; m.pourazizi@med.mui.ac.ir

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr. Mohsen Pourazizi

Study Record Dates

• First Submitted: October 23, 2021
• First Posted: October 28, 2021
• Study Start: August 23, 2021
• Primary Completion: November 21, 2021
• Study Completion: January 20, 2022
• Last Updated: October 28, 2021

Record last verified: 2021-10

Locations

IR (1)